CN107648231A - 右兰索拉唑药物制剂 - Google Patents
右兰索拉唑药物制剂 Download PDFInfo
- Publication number
- CN107648231A CN107648231A CN201610592697.5A CN201610592697A CN107648231A CN 107648231 A CN107648231 A CN 107648231A CN 201610592697 A CN201610592697 A CN 201610592697A CN 107648231 A CN107648231 A CN 107648231A
- Authority
- CN
- China
- Prior art keywords
- micropill
- enteric
- lansoprazole
- delay
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 title claims abstract description 73
- 229960003568 dexlansoprazole Drugs 0.000 title claims abstract description 66
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 19
- 229920003141 Eudragit® S 100 Polymers 0.000 claims abstract description 15
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 13
- 229960003943 hypromellose Drugs 0.000 claims abstract description 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims abstract description 3
- 238000000576 coating method Methods 0.000 claims description 95
- 239000011248 coating agent Substances 0.000 claims description 85
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 62
- 235000010603 pastilles Nutrition 0.000 claims description 59
- 239000010410 layer Substances 0.000 claims description 50
- 239000002775 capsule Substances 0.000 claims description 36
- 239000007921 spray Substances 0.000 claims description 29
- 238000000926 separation method Methods 0.000 claims description 26
- 229930006000 Sucrose Natural products 0.000 claims description 25
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 22
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 21
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 21
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 21
- 239000000853 adhesive Substances 0.000 claims description 17
- 230000001070 adhesive effect Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 238000005469 granulation Methods 0.000 claims description 16
- 230000003179 granulation Effects 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical group [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 16
- 239000001095 magnesium carbonate Substances 0.000 claims description 16
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 16
- 239000005720 sucrose Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 230000003111 delayed effect Effects 0.000 claims description 12
- -1 hydroxypropyl Chemical group 0.000 claims description 12
- 229920003139 Eudragit® L 100 Polymers 0.000 claims description 11
- 239000004014 plasticizer Substances 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 9
- 239000007884 disintegrant Substances 0.000 claims description 9
- 239000000945 filler Substances 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 239000012055 enteric layer Substances 0.000 claims description 6
- 239000001069 triethyl citrate Substances 0.000 claims description 6
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013769 triethyl citrate Nutrition 0.000 claims description 6
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000008118 PEG 6000 Substances 0.000 claims description 3
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000003605 opacifier Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 239000004408 titanium dioxide Substances 0.000 claims description 3
- 239000011806 microball Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 10
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 abstract description 8
- 238000001035 drying Methods 0.000 description 22
- 229960004793 sucrose Drugs 0.000 description 22
- 206010013786 Dry skin Diseases 0.000 description 20
- 239000012530 fluid Substances 0.000 description 17
- 239000012071 phase Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 208000021017 Weight Gain Diseases 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 230000004584 weight gain Effects 0.000 description 10
- 235000019786 weight gain Nutrition 0.000 description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 9
- 239000000835 fiber Substances 0.000 description 8
- 125000006850 spacer group Chemical group 0.000 description 8
- 229940008871 dexilant Drugs 0.000 description 7
- 239000002245 particle Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000007963 capsule composition Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 4
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010063655 Erosive oesophagitis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- NUGNRJCZHRFXDK-YUFRWXHNSA-N C/C=C\c1c(C=C)[nH]c(S(/C=C/c2nccc(OCC(F)(F)F)c2C)=O)n1 Chemical compound C/C=C\c1c(C=C)[nH]c(S(/C=C/c2nccc(OCC(F)(F)F)c2C)=O)n1 NUGNRJCZHRFXDK-YUFRWXHNSA-N 0.000 description 1
- 229920001875 Ebonite Polymers 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610592697.5A CN107648231B (zh) | 2016-07-25 | 2016-07-25 | 右兰索拉唑药物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610592697.5A CN107648231B (zh) | 2016-07-25 | 2016-07-25 | 右兰索拉唑药物制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107648231A true CN107648231A (zh) | 2018-02-02 |
CN107648231B CN107648231B (zh) | 2021-07-16 |
Family
ID=61127124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610592697.5A Active CN107648231B (zh) | 2016-07-25 | 2016-07-25 | 右兰索拉唑药物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107648231B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113842371A (zh) * | 2021-10-11 | 2021-12-28 | 江苏集萃新型药物制剂技术研究所有限公司 | 一种双相释药组合物、双相释药固体药剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101884629A (zh) * | 2002-10-16 | 2010-11-17 | 武田药品工业株式会社 | 控释制剂 |
CN103381268A (zh) * | 2012-05-04 | 2013-11-06 | 江苏豪森药业股份有限公司 | 包含质子泵抑制剂的固体药物组合物 |
CN105769824A (zh) * | 2014-12-16 | 2016-07-20 | 四川海思科制药有限公司 | 一种兰索拉唑缓释胶囊及其制备方法 |
CN105997883A (zh) * | 2016-05-06 | 2016-10-12 | 杭州容立医药科技有限公司 | 一种固体分散体及其制备方法和应用 |
-
2016
- 2016-07-25 CN CN201610592697.5A patent/CN107648231B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101884629A (zh) * | 2002-10-16 | 2010-11-17 | 武田药品工业株式会社 | 控释制剂 |
CN103381268A (zh) * | 2012-05-04 | 2013-11-06 | 江苏豪森药业股份有限公司 | 包含质子泵抑制剂的固体药物组合物 |
CN105769824A (zh) * | 2014-12-16 | 2016-07-20 | 四川海思科制药有限公司 | 一种兰索拉唑缓释胶囊及其制备方法 |
CN105997883A (zh) * | 2016-05-06 | 2016-10-12 | 杭州容立医药科技有限公司 | 一种固体分散体及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
MILIND ALAI等: "Novel Lansoprazole-Loaded Nanoparticles for the Treatment of Gastric Acid Secretion-Related Ulcers: In Vitro and In Vivo Pharmacokinetic Pharmacodynamic Evaluation", 《THE AAPS JOURNAL》 * |
王雄飞等: "右旋兰索拉唑脉冲肠溶胶囊的制备", 《中国医药工业杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113842371A (zh) * | 2021-10-11 | 2021-12-28 | 江苏集萃新型药物制剂技术研究所有限公司 | 一种双相释药组合物、双相释药固体药剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107648231B (zh) | 2021-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2600860T3 (es) | Composición farmacéutica o nutracéutica con característica de liberación retardada y con resistencia contra la influencia de etanol | |
CN1886119B (zh) | 泮托拉唑多颗粒制剂 | |
CN102579367B (zh) | 托吡酯缓释药物组合物、其制备方法及用途 | |
EP3498264B1 (en) | Pharmaceutical preparation for oral administration with controlled dissolution rate, the preparation comprising tamsulosin hydrochloride-containing sustained-release pellets | |
CN103189054B (zh) | 含有他克莫斯有效成分的缓释微丸 | |
CN112839635A (zh) | 包含埃索美拉唑及碳酸氢钠的具有优秀的释放特性的药剂学制剂 | |
CN104922086A (zh) | 一种质子泵抑制剂肠溶片的制备方法 | |
CN101513403A (zh) | 含有苯并咪唑类化合物的药物制剂 | |
CN103655480B (zh) | 一种美托洛尔的缓释药物及其制备方法 | |
KR20180015245A (ko) | 에탄올의 영향에 대한 내성을 갖는 약학적 또는 영양 보조 식품적 조성물 | |
KR20160115995A (ko) | 지속 방출 특성을 가지며 에탄올의 영향에 대한 저항성을 갖는 약제학적 또는 건강기능성 조성물 | |
US20230048354A1 (en) | Dosage form for use in treating or preventing of a disease | |
EP4072533A1 (en) | Dosage form comprising an alkaline agent and an enteric coating layer | |
CN101428005A (zh) | 泮托拉唑及其钠盐肠溶缓释微丸制剂 | |
CN103356489A (zh) | 一种质子泵抑制剂肠溶微丸及其制剂、制备方法 | |
EP4007568A1 (en) | Pharmaceutical composition comprising dabigatran etexilate | |
AU2017339246B2 (en) | Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof | |
CN105434398B (zh) | 一种雷贝拉唑肠溶微丸及其制备方法 | |
CN107648231A (zh) | 右兰索拉唑药物制剂 | |
CN104940168A (zh) | 一种右旋兰索拉唑双相缓释胶囊制剂及其制备方法 | |
US20100080846A1 (en) | Dipyridamole and acetylsalicylic acid formulations and process for preparing same | |
US11730708B2 (en) | Dosage form for use in treating or preventing of a disease | |
CN116832006A (zh) | 一种右兰索拉唑缓释微丸 | |
CN115944602A (zh) | 兰索拉唑肠溶微丸及其制备方法 | |
US20170071954A1 (en) | Pediatric cholic acid formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Drug formulation of dexamethasone Effective date of registration: 20231117 Granted publication date: 20210716 Pledgee: Industrial and Commercial Bank of China Limited Lianyungang Economic and Technological Development Zone sub branch Pledgor: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2023980066019 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210716 Pledgee: Industrial and Commercial Bank of China Limited Lianyungang Economic and Technological Development Zone sub branch Pledgor: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2023980066019 |